JSA Advises Multiples Private Equity Fund's Investment In BDR Pharmaceuticals

BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores.

20 May, 2022 by BW Online Bureau

Print this article Font size -16+

Multiples Private Equity Fund’s investment in BDR Pharmaceuticals International Private Limited

JSA advised and represented Multiples Private Equity Fund (“Multiples”) in an investment of INR 685 crores by a consortium of investors led by Multiples for a 9.3% stake in BDR Pharmaceuticals International Private Limited (“BDR Pharma”). This is the first investment into the company.

BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores. The company focuses on therapeutic segments such as oncology and critical care with a growing presence in dermatology and gynaecology. BDR Pharma shot to fame during Covid-19 for developing copies of antivirals such as remdesivir, favipiravir, molnupiravir and lyophilized amphotericin b injection.

JSA team comprised